Doctors are pushing the FDA to remove black box warnings on low-dose estrogen treatments, arguing it discourages women from beneficial hormone therapies for menopause. Experts claim the risks are overstated and can hinder treatment.
Recent clinical trials show that GLP-1 weight loss medications like Zepbound are more effective for women than men, prompting researchers to explore the biological and societal reasons behind this phenomenon.
